{"id":305055,"date":"2026-04-29T00:00:00","date_gmt":"2026-04-29T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0001-2024-biopharma-heart-failure-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-06-05T23:14:59","modified_gmt":"2026-06-05T23:14:59","slug":"dlsfcv0001-2026-biopharma-heart-failure-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0001-2026-biopharma-heart-failure-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Heart Failure &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Heart failure (<abbr data-abbreviation-entity=\"6459\" title=\"heart failure\">HF<\/abbr>) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (<abbr data-abbreviation-entity=\"6452\" title=\"acute heart failure\">AHF<\/abbr>) and chronic heart failure (<abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr>) have distinct treatment pathways, and both are covered in this report. The <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr> therapy market will expand over the 2024-2034 forecast period, driven by increased prevalence and polypharmacy along with the entry of new agents. <abbr data-abbreviation-entity=\"5590\" title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors have established themselves as the <abbr data-abbreviation-entity=\"7712\" title=\"standard of care\">SOC<\/abbr> for <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr> (regardless of <abbr data-abbreviation-entity=\"8184\" title=\"ejection fraction\">EF<\/abbr>), owing to their robust cardioprotective profile. Nevertheless, despite these advances, substantial unmet needs remain in the treatment of <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr>. We forecast several therapies to launch for heart failure with preserved ejection fraction (<abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr>) during the forecast period, including Bayer\u2019s finerenone, Novo Nordisk\u2019s ziltivekimab, Boehringer Ingelheim\u2019s vicadrostat, and AstraZeneca\u2019s balcinrenone \/ dapagliflozin <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the incidence of <abbr data-abbreviation-entity=\"6452\" title=\"acute heart failure\">AHF<\/abbr> events and the prevalence of <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr> cases in the major pharmaceutical markets under study?<\/li>\n<li>What are the drivers and constraints in the heart failure therapy market, and how will the market evolve through 2034?<\/li>\n<li>What are the greatest unmet needs in the treatment of heart failure? Which drugs in development will fulfill these unmet needs?<\/li>\n<li>How will the treatment of <abbr data-abbreviation-entity=\"6460\" title=\"heart failure with preserved ejection fraction\">HFpEF<\/abbr> evolve following the launch of novel therapies for this population?<\/li>\n<li>Which emerging therapies generate the most enthusiasm among thought leaders, and what is the expected level of market penetration of these agents?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/li>\n<li><strong>Primary research: <\/strong>Country-specific interviews with thought-leading cardiologists. Survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology:<\/strong> Diagnosed events of <abbr data-abbreviation-entity=\"6452\" title=\"acute heart failure\">AHF<\/abbr> by country and diagnosed prevalence of <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr> by country, segmented by ejection fraction.<\/li>\n<li><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies.<\/li>\n<li><strong>Market forecast features: <\/strong>10-year, annualized, drug-level sales and patient share of key heart failure therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW116218351 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305055","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-heart-failure","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305055\/revisions"}],"predecessor-version":[{"id":580404,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305055\/revisions\/580404"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}